Mesa Laboratories/$MLAB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Mesa Laboratories

Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.

Ticker

$MLAB
Sector
Primary listing

Employees

730

MLAB Metrics

BasicAdvanced
$403M
-
-$0.11
0.82
$0.64
0.87%

What the Analysts think about MLAB

Analyst ratings (Buy, Hold, Sell) for Mesa Laboratories stock.

Bulls say / Bears say

FY25 total revenues were $240.98 million, up 11.5% year-over-year, with non-GAAP adjusted operating income rising 12.3% to $56.7 million, demonstrating strong multi-division growth and improved operational efficiency (GlobeNewswire)
Mesa completed the integration of the GKE acquisition in nine months, outperforming initial revenue and profitability targets and strengthening the scale and cross-selling abilities of its SDC division (GlobeNewswire)
In Q1 FY26, the Sterilization and Disinfection Control segment achieved 7.5% core organic revenue growth and a 370 basis point gross margin improvement, supported by strong order fulfillment and clearing of backlog (Mesa Labs investors)
The Clinical Genomics division’s core organic revenues dropped 10.7% in Q1 FY26, mainly because China sales fell 69% amid macroeconomic and regulatory challenges (Mesa Labs investors)
Biopharmaceutical Development revenues decreased by 7.0% on a core organic basis in Q1 FY26 owing to order timing and shipping delays, highlighting the segment's variability (Mesa Labs investors)
Wells Fargo lowered its price target for MLAB from $100 to $67, and Wall Street Zen downgraded the stock to 'hold', signaling analyst concerns over valuation and short-term growth prospects (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.

MLAB Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MLAB Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MLAB

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs